Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70

Alzheimer’s disease has a preclinical stage when cerebral amyloid-β deposition occurs before symptoms emerge, and when amyloid-β-targeted therapies may have maximum benefits. Existing amyloid-β status measurement techniques, including amyloid PET and CSF testing, are difficult to deploy at scale, so...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshavan, Ashvini, Pannee, Josef, Karikari, Thomas K, Rodriguez, Juan Lantero, Ashton, Nicholas J, Nicholas, Jennifer M, Cash, David M, Coath, William, Lane, Christopher A, Parker, Thomas D, Lu, Kirsty, Buchanan, Sarah M, Keuss, Sarah E, James, Sarah-Naomi, Murray-Smith, Heidi, Wong, Andrew, Barnes, Anna, Dickson, John C, Heslegrave, Amanda, Portelius, Erik, Richards, Marcus, Fox, Nick C, Zetterberg, Henrik, Blennow, Kaj, Schott, Jonathan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940173/
https://www.ncbi.nlm.nih.gov/pubmed/33479777
http://dx.doi.org/10.1093/brain/awaa403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940173/
https://www.ncbi.nlm.nih.gov/pubmed/33479777
http://dx.doi.org/10.1093/brain/awaa403

Ejemplares similares